---
schema_version: "secwatch.filing_event.v1"
accession: "0001819790-25-000077"
form_type: "8-K"
ticker: "TARS"
cik: "0001819790"
company_name: "Tarsus Pharmaceuticals, Inc."
filed_at: "2025-05-01T23:59:59+00:00"
generated_at: "2026-05-23T00:57:08.309003+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Tarsus Q1 2025: XDEMVY sales $78.3M, up 217% YoY; net loss narrows to $25.1M

## Summary
- Net product sales of XDEMVY $78.3M, up 217% vs Q1 2024 and 18% vs Q4 2024; ~72,000 bottles dispensed.
- Net loss of $25.1M ($0.64 diluted loss per share), improved from $35.7M loss ($1.01 per share) in Q1 2024.
- Cash, cash equivalents and marketable securities $407.9M as of March 31, 2025, bolstered by $134.8M equity offering.
- SG&A expenses $85.0M, up from $51.6M, driven by DTC advertising and commercial expansion.
- On track to initiate Phase 2 trial of TP-04 for Ocular Rosacea in H2 2025.

## SEC filing metadata
- accession: 0001819790-25-000077
- form_type: 8-K
- ticker: TARS
- cik: 0001819790
- company_name: Tarsus Pharmaceuticals, Inc.
- filed_at: 2025-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819790/000181979025000077/0001819790-25-000077-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819790/000181979025000077/tars-20250501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001819790-25-000077
- JSON: https://secwatch.observer/filing/0001819790-25-000077.json
- Plain text: https://secwatch.observer/filing/0001819790-25-000077.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.